Hugh Laverty

1.7k total citations · 1 hit paper
17 papers, 1.1k citations indexed

About

Hugh Laverty is a scholar working on Molecular Biology, Dermatology and Rehabilitation. According to data from OpenAlex, Hugh Laverty has authored 17 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Dermatology and 4 papers in Rehabilitation. Recurrent topics in Hugh Laverty's work include Computational Drug Discovery Methods (4 papers), Wound Healing and Treatments (4 papers) and Dermatologic Treatments and Research (4 papers). Hugh Laverty is often cited by papers focused on Computational Drug Discovery Methods (4 papers), Wound Healing and Treatments (4 papers) and Dermatologic Treatments and Research (4 papers). Hugh Laverty collaborates with scholars based in United Kingdom, United States and Germany. Hugh Laverty's co-authors include Sharon O’Kane, Nick L. Occleston, Mark W. J. Ferguson, Joanna B. Wilson, Christopher E. Goldring, Dominic P. Williams, Tracey Mason, Craig Lambert, Dennis A. Smith and Stephen E. Clarke and has published in prestigious journals such as The Lancet, Nature Reviews Drug Discovery and Cell stem cell.

In The Last Decade

Hugh Laverty

17 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Managing the challenge of chemically reactive metabolites in drug development

2011 338 citations B. Kevin Park, Alan R. Boobis et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hugh Laverty United Kingdom	10	439	235	201	175	145	17	1.1k
Mike Walker United Kingdom	16	419 1.0×	149 0.6×	46 0.2×	115 0.7×	94 0.6×	30	1.1k
Zhen Gao China	22	437 1.0×	179 0.8×	35 0.2×	85 0.5×	240 1.7×	60	1.0k
Sehwan Shim South Korea	22	327 0.7×	49 0.2×	97 0.5×	111 0.6×	39 0.3×	52	986
Ye Cheng China	19	1.2k 2.8×	174 0.7×	37 0.2×	142 0.8×	25 0.2×	59	2.1k
Katiuscia Dallaglio Italy	21	1.0k 2.4×	61 0.3×	47 0.2×	98 0.6×	81 0.6×	31	1.8k
Hitomi Fujisaki Japan	19	476 1.1×	55 0.2×	41 0.2×	117 0.7×	46 0.3×	60	1.0k
Levi Fried United States	12	408 0.9×	202 0.9×	84 0.4×	84 0.5×	41 0.3×	13	860
Shiou Zhu China	11	669 1.5×	166 0.7×	21 0.1×	66 0.4×	28 0.2×	13	1.1k
Sarvajit Chakravarty United States	22	773 1.8×	21 0.1×	53 0.3×	81 0.5×	19 0.1×	39	1.6k

Countries citing papers authored by Hugh Laverty

Since Specialization

Citations

This map shows the geographic impact of Hugh Laverty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugh Laverty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugh Laverty more than expected).

Fields of papers citing papers by Hugh Laverty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugh Laverty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugh Laverty. The network helps show where Hugh Laverty may publish in the future.

Co-authorship network of co-authors of Hugh Laverty

This figure shows the co-authorship network connecting the top 25 collaborators of Hugh Laverty. A scholar is included among the top collaborators of Hugh Laverty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugh Laverty. Hugh Laverty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Laverty, Hugh & Pierre Meulien. (2019). The Innovative Medicines Initiative −10 Years of Public-Private Collaboration. Frontiers in Medicine. 6. 275–275. 22 indexed citations

Laverty, Hugh, Kristina M. Orrling, Fabrizio Giordanetto, et al.. (2016). The European lead factory—an experiment in collaborative drug discovery. 1(1). 5 indexed citations

Laverty, Hugh, Kristina M. Orrling, Fabrizio Giordanetto, et al.. (2015). The European lead factory—an experiment in collaborative drug discovery. 1(1). 20–20. 9 indexed citations

Laverty, Hugh, et al.. (2014). IP Policy Forum: Intellectual Property Rights (IPR) In Collaborative Drug Development in the EU: Helping a European Public-Private Partnership Deliver - The Need for a Flexible Approach to IPR. 18(1). 31. 2 indexed citations

Ecker, Gerhard F., et al.. (2014). ‘Big Data’ in Pharmaceutical Science: Challenges and Opportunities. Future Medicinal Chemistry. 6(8). 857–864. 7 indexed citations

Wittelsberger, Angela, Michel Goldman, & Hugh Laverty. (2014). Building new models of drug discovery in Europe: The Innovative Medicines Initiative. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 15(2). 49–54. 1 indexed citations

Park, B. Kevin, Alan R. Boobis, Stephen E. Clarke, et al.. (2011). Managing the challenge of chemically reactive metabolites in drug development. Nature Reviews Drug Discovery. 10(4). 292–306. 338 indexed citations breakdown →

Goldring, Christopher E., Paul Duffy, Nissim Benvenisty, et al.. (2011). Assessing the Safety of Stem Cell Therapeutics. Cell stem cell. 9(2). 176–176. 7 indexed citations

Occleston, Nick L., Sharon O’Kane, Hugh Laverty, et al.. (2011). Discovery and development of avotermin (recombinant human transforming growth factor beta 3): A new class of prophylactic therapeutic for the improvement of scarring. Wound Repair and Regeneration. 19(s1). s38–48. 68 indexed citations

10.

Goldring, Christopher E., Paul Duffy, Nissim Benvenisty, et al.. (2011). Assessing the Safety of Stem Cell Therapeutics. Cell stem cell. 8(6). 618–628. 175 indexed citations

11.

Madesis, Panagiotis, et al.. (2011). A synthetic gene increases TGFβ3 accumulation by 75‐fold in tobacco chloroplasts enabling rapid purification and folding into a biologically active molecule. Plant Biotechnology Journal. 9(5). 618–628. 30 indexed citations

12.

Laverty, Hugh, et al.. (2010). The potential of cytokines as safety biomarkers for drug-induced liver injury. European Journal of Clinical Pharmacology. 66(10). 961–976. 49 indexed citations

13.

Laverty, Hugh, Nick L. Occleston, Mark Johnson, et al.. (2010). Effects of Avotermin (Transforming Growth Factor β₃) in a Clinically Relevant Pig Model of Long, Full-Thickness Incisional Wounds. Journal of Cutaneous Medicine and Surgery. 14(5). 223–232. 5 indexed citations

14.

Ferguson, Mark W. J., Jonathan Duncan, Jeremy S. Bond, et al.. (2009). Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. The Lancet. 373(9671). 1264–1274. 215 indexed citations

15.

Occleston, Nick L., Hugh Laverty, Sharon O’Kane, & Mark W. J. Ferguson. (2008). Prevention and reduction of scarring in the skin by Transforming Growth Factor beta 3 (TGFβ3): from laboratory discovery to clinical pharmaceutical. Journal of Biomaterials Science Polymer Edition. 19(8). 1047–1063. 109 indexed citations

16.

Stevenson, David, et al.. (2000). Mapping and expression analysis of the human CASK gene. Mammalian Genome. 11(10). 934–937. 26 indexed citations

17.

Laverty, Hugh & Joanna B. Wilson. (1998). Murine CASK Is Disrupted in a Sex-Linked Cleft Palate Mouse Mutant. Genomics. 53(1). 29–41. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact